Erasca, Inc. (ERAS) Stock Price & How to Invest

Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company developing therapies for cancers driven by the RAS/MAPK signaling pathway, one of the most common and historically hardest-to-drug drivers in tumors like non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Its prioritized pipeline centers on ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, an oral pan-KRAS inhibitor, both in Phase 1 trials (AURORAS-1 and BOREALIS-1). The company reported positive preliminary Phase 1 dose-escalation data for ERAS-0015 in 2026, showing responses in KRAS-mutant lung and pancreatic cancer, and in mid-2026 it discontinued its former lead asset naporafenib and terminated the related Novartis license to concentrate resources on the RAS-targeting franchise.

As a development-stage biotech, Erasca has no approved products and no meaningful product revenue, so it runs large operating losses funded by its balance sheet and equity raises. It ended Q1 2026 with roughly $408 million in cash and marketable securities and later raised about $550 million more in a July 2026 stock offering, pushing projected runway well past 2028 but also diluting existing holders. The investment picture is therefore driven almost entirely by clinical readouts, the pace toward potential registration-enabling trials, and how ERAS-0015 stacks up against rival RAS programs, all against a market capitalization in the multi-billion-dollar range that already prices in substantial future success.

Erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. Early Phase 1 response data are preliminary, involve small patient numbers, and may not hold up in larger, controlled studies. The company competes directly with better-financed RAS programs, most notably Revolution Medicines, whose daraxonrasib has shown strong pancreatic-cancer survival data. Ongoing losses mean further dilutive equity raises are likely, and the multi-billion-dollar market cap already assumes substantial clinical and commercial success that is far from guaranteed.

10 analysts publish price targets on ERAS, averaging $22.80 against a $18.15 price as of August 2026, or +25.6%. The published targets run from $18.00 to $30.00, a moderate spread, and the ratings split 8 buy, 2 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ERAS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Erasca, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. RAS/MAPK is a large, underserved target. RAS mutations drive a meaningful share of lung, pancreatic, and colorectal cancers and have long been considered difficult to drug. The most optimistic published target, $30.00, assumes this works close to its best case.

The case against. Erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. The most pessimistic target, $18.00, is roughly what ERAS is worth if this bites instead.

Read the full bull and bear case on ERAS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Erasca, Inc.'s investor relations page or your broker.

• Product revenue: ~$0 (no approved products)
• Q1 2026 net loss: ~$183M (incl. ~$150M licensing charge)
• Q1 2026 R&D (ex one-time item): ~$27M
• Cash (end Q1 2026): ~$408M
• Additional July 2026 raise: ~$550M at $17.50/share
• Market cap: ~$5.6B to $6B

Because Erasca has no product sales, standard valuation multiples like P/E do not apply, and the company is valued on its cash position and the perceived probability that its RAS pipeline succeeds. The heavy Q1 2026 net loss was inflated by a large one-time licensing milestone, while underlying operating spend is more modest. The mid-2026 equity raise pushed projected runway past 2028 but increased shares outstanding.

If you want ERAS exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to ERAS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ERAS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XBI), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ERAS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ERAS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Erasca is a pre-revenue, RAS-focused biotech whose value rests on pipeline data and cash runway, not earnings, which makes it a high-volatility, binary-outcome name.

Whether ERAS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ERAS a buy or a sell?, and where the stock could go from here in the ERAS stock forecast.

For income investors, whether ERAS pays a dividend and how the payout looks is covered in does ERAS pay a dividend? And to weigh ERAS against a peer, read the full side-by-side comparisons: ERAS vs AMGN and ERAS vs BMY.